|____Semperform____|___________________|___________________|___________________| 
|____Umsatzerlöse__|_______________19,8|______________-0,3%|_______________19,9| 
|____EBITDA________|________________3,1|_____________-11,9%|________________3,5| 
|____EBIT__________|________________2,1|_____________-16,3%|________________2,6| 
|____Semperseal____|___________________|___________________|___________________| 
|____Umsatzerlöse__|_______________28,7|______________13,1%|_______________25,4| 
|____EBITDA________|________________4,2|______________29,5%|________________3,3| 
|____EBIT__________|________________2,6|______________50,8%|________________1,8| 
|Sektor Medizin    |                   |                   |                   | 
|(Sempermed)_______|___________________|___________________|___________________| 
|Umsatzerlöse______|______________192,9|______________>100%|_______________77,5| 
|EBITDA____________|______________105,3|______________>100%|________________4,8| 
|EBIT______________|______________100,2|______________>100%|________________4,3| 
 
 
 
 
 
 
 
 
Rückfragehinweis: 
Monika Riedel 
Director Group Brand Management, Corporate Spokesperson 
+43 676 8715 8620 
monika.riedel@semperitgroup.com 
 
Judit Helenyi 
Director Investor Relations 
+43 676 8715 8310 
judit.helenyi@semperitgroup.com 
 
www.semperitgroup.com 
 
Ende der Mitteilung                               euro adhoc 
=------------------------------------------------------------------------------- 
 
 
Anhänge zur Meldung: 
=--------------------------------------------- 
http://resources.euroadhoc.com/documents/15/5/10725755/0/2021-05-19_Semperit_Presseinformation_Q1_2021.pdf

(END) Dow Jones Newswires

May 19, 2021 01:39 ET (05:39 GMT)